About thirty years ago, epidemiological and genetic linkage studies of multiple-case families have guided the identification of TP53 mutations as a cause of Li-Fraumeni Syndrome [4-6] and of BRCA1 and BRCA2 as first genes in which mutations strongly predispose to breast and ovarian cancer [7,8]. The gene discussed is TP53; the disease is ovarian carcinoma.